Home › Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
 

Keywords :   


Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)

2014-03-05 04:59:35| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, recently announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Tags: data presented conference 21st

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Ryanair profits surge after fares climb by 20%
20.05Vidzemes TV expands with PlayBox Neo Channel-in-a-Box playout
20.05ocilion enhances user experience with Simply.TV metadata
20.05Vantiva RDK device shipments exceed 125 million
20.05VinFast first with Sony Pictures in-car service
20.05LG Ad Solutions to adopt Unified ID 2.0
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
More »